Objective: The purpose of this consensus conference was to develop and update evidence-informed consensus statements and recommendations on harvesting saphenous vein and radial artery via an open as compared with endoscopic technique by systematically reviewing and performing a meta-analysis of randomized and nonrandomized clinical trials. Methods: All randomized controlled trials and nonrandomized controlled trials included in the first the International Society for Minimally Invasive Cardiothoracic Surgery Consensus Conference and Statements, 1,2 in 2005 up to November 30, 2015, were included in a systematic review and meta-analysis. Based on the resultant, 76 studies (23 randomized controlled trials and 53 nonrandomized controlled trials) on 281,459 patients analyzed, consensus statements, and recommendations were generated comparing the risks and benefits of endoscopic versus open conduit harvesting for patients undergoing coronary artery bypass grafting.
C oronary artery bypass grafting (CABG) is the most common surgical revascularization procedure and the most common cardiac surgical procedure performed worldwide. Conduit harvest, either greater saphenous vein and/or radial artery, has traditionally been performed using an open technique, which has been associated with excellent outcomes, but with issues related to wound healing and discomfort. A minimally invasive approach via endoscopic vein harvest (EVH) of saphenous vein or endoscopically harvested radial artery (ERAH) would offer the potential for less morbidity and patient discomfort. This endoscopic technique has been adapted to varying degree for these potential advantages. In 2005, the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) convened and subsequently published a consensus statement and meta-analysis of the literature on EVH to provide guidance to surgeons on the best available scientific evidence on this topic. 1, 2 In the interim, controversy has been generated from a retrospective post hoc analysis of a vein harvesting trial regarding the safety of endoscopic harvest casts doubt on best medical practice. 3 In addition, further studies on endoscopic harvesting of saphenous vein as well as radial artery have been added to the medical literature as this field has progressed. A lack of clarity due to conflicting reports and additional studies published since the original ISMICS consensus statements have been the impetus for an updated analysis of the available literature to provide guidance on endoscopic harvesting based on high-quality evidence.
OBJECTIVE
We investigated whether endoscopic conduit harvesting (saphenous vein or radial artery) improves clinical and resource outcomes compared with conventional open graft harvesting in adult patients undergoing CABG surgery. This systematic review and meta-analysis is an update of the ISMICS 2005 meta-analysis on EVH in CABG surgery. 2 
METHODS
This systematic review and meta-analysis used stateof-the-art methodological recommendations (ie, Cochrane Collaboration), 4 based on a protocol that prespecified search strategies, inclusion and exclusion criteria, outcomes and statistical analysis plan.
Definition of Clinical and Resource Outcomes
The primary outcome was defined as the incidence of wound infection or cellulitis at the harvest site. Secondary outcomes included wound complications (ie, abscess, necrosis, dehiscence, drainage, seromas, lymphocele, edema, and hematoma), endothelial damage score, medial continuity, venous repair stitches, harvest vein repairs, angiographic graft failure or occlusion, postoperative, short-and long-term angiographic patency rates, myocardial infraction at 30 days, perioperative mortality (30 days), long-term mortality (up to 4 years), composite of death, myocardial infarction or revascularization up to 4 years, pain, satisfaction, mobility, sensory dysfunction, number of grafts performed, harvest site, harvest time, closure time, operating time, resource use including antibiotics, surgical intervention for wound complications, length of stay (LOS), nursing or home care services, readmission for wound complications, and emergency room or physician visits.
Wound infections were defined as per the included studies and included cellulitis when "wound infection" was not separately reported as such. Wound complications were defined as per the included studies, and were only reported when the included studies reported the outcome "wound complications." Wound complications typically comprised a combination of wound problems including infection, cellulitis, abscess, drainage, seroma, lymphocele, dehiscence, necrosis, hematoma and inflammation. It should be noted that patients with one wound complication often experience additional complications (eg, infection with abscess and drainage). To avoid unit of analysis errors (ie, double counting of patients), we did not sum separate types of wound complications reported by individual studies to create a composite for wound complications. Surgical interventions for wound complications included wound debridement, amputation, fasciotomy, and tissue flaps. The quality of the harvested conduit was assessed using a number of outcomes including venous repair stitches, harvest vein repair, endothelial damage scores (scored 1 to 5, with 5 indicating maximum damage or no integrity), medial continuity scores, injury to conduit, major coronary adverse events, postoperative, short-and long-term angiographic patency rates, angiographic graft failure and occlusion rates. Major coronary adverse events were defined as per the included studies and included all-cause mortality, myocardial infarction, stroke, angina recurrence or reintervention due to ischemia. Myocardial infarction was defined as per the included studies.
Literature Search
We searched MEDLINE, EMBASE, and the Cochrane Library (CENTRAL) from January 1, 2005, to November 30, 2015 . The comprehensive search strategy is reported in Appendix 1 (Supplemental Digital Content, http://links.lww.com/INNOV/ A149). Conference abstracts and the references of relevant systematic reviews and included studies were searched to identify additional eligible studies. There were no limits placed on study design, language of publication, or publication status (published or unpublished).
Inclusion Criteria
Randomized controlled trials (RCTs) and nonrandomized observational studies including prospective or retrospective cohort and case-control studies were considered for inclusion. Adult patients undergoing on-or off-pump CABG were considered for inclusion. Studies had to compare EVH or radial artery harvest with a traditional open harvest approach to be included. Studies that combined surgical procedures or evaluated robotic surgery were excluded. Studies that evaluated minimally invasive harvest techniques that were not endoscopic were excluded.
Data Extraction and Management
A standardized data extraction sheet was developed to record the following data from the included studies: study design, baseline demographics including number of patients, inclusion and exclusion criteria, age, sex, diabetes, obesity, peripheral vascular disease, on or off-pump CABG, primary and secondary outcome measures, and duration of follow-up. At least two authors independently extracted outcome data. Any discrepancies were resolved by discussion and consensus.
Assessment of Methodological Quality
We used the Cochrane Collaboration risk of bias tool to assess the methodological quality of RCTs. 4 The factors that were assessed included the following: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias. Based on these factors, we rated the studies as low, unclear, or high risk of bias. We contacted study authors for additional information if any items being assessed were unclear. We assessed the methodological quality of cohort and case-control studies using the Newcastle-Ottawa Scale. 5 
Data Analysis
Data from individual trials were pooled for meta-analysis if the interventions, patient groups, and outcomes were sufficiently similar (determined by consensus). For dichotomous outcomes, we calculated the odds ratio (OR) and corresponding 95% confidence interval (95% CI). For continuous outcomes, we calculated the mean difference (MD) and corresponding 95% CI. If different scales were used to measure the same underlying construct, we calculated the standardized MD and corresponding 95% CI as appropriate. Meta-analysis was carried out using a random-effects model. A statistically significant overall effect was defined as P value of less than 0.05 or as a 95% CI that did not cross the line of no effect (ie, 1 for OR and 0 for MD or standardized MD). We assessed heterogeneity among studies using the χ 2 test. A P value of ≤ 0.10 was regarded as statistically significant for the χ 2 test. The I 2 statistic was used to quantify heterogeneity. This statistic describes the percentage of total variation across studies that results from heterogeneity rather than chance. A value of 25% is considered to indicate low heterogeneity, 50% moderate heterogeneity, and 75% high heterogeneity. 6 Subgroup analysis was planned for randomized and nonrandomized studies. We explored publication bias through visual inspection of funnel plots as appropriate (ie, when ≥10 studies were included in a pooled analysis). We used the Cochrane Collaboration Review Manager software (RevMan Version 5.3) for the statistical analysis. 7 
Consensus Conference
A consensus conference was organized by the ISMICS to clarify the role of endoscopic vein or radial harvest compared with open harvest in adults undergoing CABG surgery. The primary objective of the consensus conference was to provide the best available evidence for the question: "Does endoscopic vein or radial graft harvesting compared with conventional open harvesting in adults undergoing CABG improve clinical and resource outcomes?" The consensus conference panel members were selected based on content and/or methodologic expertise. An additional panel member (J.K.M.) was invited based on his expertise in evidence-based medicine, systematic reviews, and meta-analysis. The American College of Cardiology and American Heart Association Clinical Practice Guideline Recommendation Classification System was used to assess the overall quality of evidence and the strength of recommendations. 8 
RESULTS
The literature search identified 16,368 records. Forty-two records (describing 36 studies) were identified from the 2005 meta-analysis. 2 One additional study was identified through searching the reference sections of systematic reviews. 9 After duplicates were removed, a total of 15,141 studies remained for review of titles and abstracts. After the titles and abstracts of these trials were reviewed, 107 studies were selected for full text review (Fig. 1 ). Eleven reports of 10 studies were excluded. Three excluded studies were published protocols for RCTs. [10] [11] [12] Five studies were excluded because no usable data were reported. [13] [14] [15] [16] [17] One study was excluded because both saphenous vein and radial artery harvest were used without reporting separate results for each type of harvest. 18 One study was excluding for using a bridging technique that was not considered to be true endoscopic harvest. 19 Ninety-six reports of 76 studies met the predefined inclusion criteria and were included in the review. Twenty-three studies were RCTs and included a total of 2332 randomized patients, and 53 studies including a total of 279,127 patients were nonrandomized case-control and cohort studies. 3, 9, In total, the 76 studies included 281,459 patients. All of the included studies were published. Five studies were published in languages other than English. 30, 39, 57, 70, 108 The 2005 meta-analysis included 13 RCTs and 23 nonrandomized case-control and cohort studies. The characteristics and methodological quality of these studies have been described elsewhere.
2 Tables 1 and 2 report the characteristics of the RCTs and nonrandomized studies identified by the updated literature search. Sixty two of the studies compared EVH with open vein harvest (OVH) and 14 studies compared ERAH with open radial artery harvest (ORAH). Although most of the studies were conducted in the United States, several European and Asian countries were also represented.
The risk of bias assessment for the 10 RCTs identified by the updated literature search is reported in Figure 2 . All of the RCTs were rated as high risk of bias for blinding. The methodological quality assessment (Newcastle-Ottawa Scale) for the 30 nonrandomized studies identified by the updated literature search is reported in Table 3 . Total scores on this scale can range from a value of 0 to 9 with 9 indicating high methodological quality. Most of the studies were judged to be of reasonably good quality with three studies receiving scores of 9, nine studies receiving scores of 8, four studies receiving scores of 7, five studies receiving scores of 6, and seven studies receiving scores of 5. Two studies were not assessed because they were published in Dutch and Chinese. 57, 70 Although all of the included studies were at risk for performance or detection bias because it was not possible to blind physicians, patients, and personnel to the intervention, many of the outcomes assessed in this systematic review are objective in nature (eg, postoperative infection) and are not likely to be influenced by performance or detection bias. Visual inspection of funnel plots found no clear evidence of publication bias. However, inadequate power for some clinical outcomes prevented an adequate analysis of bias. Table 4 summarizes patient baseline characteristics for the studies comparing EVH with OVH. The mean age at baseline for participants in the studies comparing EVH with OVH was 64.3 years. Thirty percent of these participants were female, 37% had diabetes, 18% were obese, and 18% had peripheral vascular disease. Baseline characteristics did not differ significantly between EVH and OVH groups in the randomized studies. However, in nonrandomized studies, the EVH group had significantly fewer females (30% vs 32%, P = 0.0002), was more likely to have diabetes (38% vs 36%, P = 0.02), and had significantly higher mean body mass index scores (P < 0.00001). A baseline imbalance in key prognostic factors may be evidence of selection bias, whereby patients who were male or had diabetes or were obese were selected for endoscopic treatment because of the perception that they would likely benefit from EVH. Table 5 summarizes patient baseline characteristics for the studies comparing ERAH with ORAH. The mean age at baseline for participants in the studies comparing ERAH with ORAH was 60.3 years. Eighteen percent of these participants were female, 36% had diabetes, and 10% had peripheral vascular disease. Baseline characteristics did not differ significantly between ERAH and ORAH groups in the randomized studies or the nonrandomized studies. Tables 6 and 7 summarize the clinical and resource outcomes for the studies comparing EVH with OVH and ERAH with ORAH, respectively.
Wound Complications
Question: Does EVH reduce wound complications when compared with OVH in CABG surgery?
EVH Versus OVH
A pooled analysis of 29 studies including 11,919 patients showed that the odds of wound complications were significantly reduced by 71% with EVH compared with OVH (OR = 0.29, 95% CI = 0.22 to 0.37, P < 0.00001) (Fig. 3) . This benefit was statistically significant for both nonrandomized and randomized studies with an odds reduction of 69% in the nonrandomized studies (OR = 0.31, 95% CI = 0.22 to 0.42) and 76% in the randomized studies (OR = 0.24, 95% CI = 0.14 to 0.43). Significant heterogeneity was detected for the nonrandomized studies (I 2 = 49%) but not for the randomized studies (I 2 = 1%). Similarly, a pooled analysis of 42 studies including 31,677 patients showed that the odds of wound infection were significantly reduced by 71% with EVH compared with OVH (OR = 0.29, 95% CI = 0.22 to 0.39, P < 0.0001). This benefit was statistically significant for both nonrandomized and randomized studies with an odds reduction of 69% in the nonrandomized studies (OR = 0.31, 95% CI = 0.23 to 0.43, I 2 = 50%) and 76% in the randomized studies (OR = 0.24, 95% CI = 0.14 to 0.43, 
Recommendation
We recommend EVH to reduce wound-related complications including wound infection or cellulitis (class I, level A).
Question: Does ERAH reduce wound complications when compared with ORAH in CABG surgery?
ERAH Versus ORAH
A pooled analysis of 10 studies including 1368 patients showed that the odds of wound infection were significantly reduced by 72% with ERAH compared with ORAH (OR = 0.28, 95% CI = 0.13 to 0.63, I 2 = 0%, P = 0.002) (Fig. 4) . This benefit was statistically significant for the nonrandomized studies (OR = 0.31, 95% CI = 0.13 to 0.77) but not for the randomized 
Statements

ERAH significantly reduces wound infection or cellulitis compared with ORAH (level B-R) 2. ERAH is associated with a reduction in the incidence of hematoma (level B-R)
Recommendation
We recommend ERAH to reduce wound-related complications including wound infection and hematoma (class I, level B-R).
Quality of Harvested Conduit
Question: Does EVH compromise the quality of conduit harvested when compared with OVH in CABG?
Question: Does EVH result in an increase in major adverse cardiac events or vein graft occlusion when compared with OVH in CABG?
EVH Versus OVH
The mean number of venous repair stitches was increased by a mean of 1.09 stitches per patient with EVH compared with OVH (95% CI = 0.89 to 1.29, 5 studies, 692 patients, P < 0.00001). Similarly, the odds of requiring harvest vein repair during the harvest procedure were significantly increased in EVH patients compared with OVH patients (OR = 2.99, 95% CI = 1.18 to 7.61, 8 studies, 978 patients, P = 0.02). There was no statistically significant difference in endothelial damage score (MD = −0.09, 95% CI = −0.27 to 0.09, 3 studies, 479 patients, P = 0.33) or medial continuity score (MD = 0.00, 95% CI = −0.22 to 0.22, 1 study, 309 patients, P = 1.00).
A pooled analysis of 15 studies including 17,801 patients showed no statistically significant difference in myocardial infarction rates at 30 days between EVH and OVH (OR = 0.89, 95% CI = 0.69 to 1.14, P = 0.35). Similarly, there was no statistically significant difference in myocardial infarction at 1 year (OR = 0.60, 95% CI = 0.12 to 3.02, 2 studies, 1540 patients, P = 0.53). A pooled analysis of six studies including 1297 patients showed no statistically significant difference in Few trials reported on angiographic outcomes. A pooled analysis of three studies including 769 patients showed the odds of angiographic occlusion up to 6 months' follow-up were not significantly increased in EVH patients compared with OVH patients (OR = 1.15, 95% CI = 0.75 to 1.76, P = 0.66). This result was not statistically significant for nonrandomized studies (OR = 0.84, 95% CI = 0.38 to 1.86, P = 0.67) or randomized studies (OR = 1.30, 95% CI = 0.79 to 2.15, P = 0.30). A pooled analysis of two nonrandomized studies including 326 patients showed the odds of angiographic vein graft failure or occlusion at 1 year were significantly increased in EVH patients compared with OVH patients (OR = 1.73, 95% CI = 1.32 to 2.26, P < 0.0001). A pooled analysis of four studies including 2389 patients that provided follow-up data at greater than 1 year showed the odds of angiographic graft failure or occlusion were nonsignificantly increased in EVH patients compared with OVH patients (OR = 1.58, 95% CI = 0.92 to 2.71, P = 0.10). 
Recommendations
Based on quality of conduit harvested, EVH is noninferior to OVH technique (class IIa, level B-R).
Based on major adverse cardiac events and angiographic patency, EVH is noninferior to OVH technique (class III no benefit, level B-NR).
Question: Does ERAH result in an increase in major adverse cardiac events or graft occlusion when compared with ORAH in CABG?
ERAH Versus ORAH
A pooled analysis of seven studies including 2156 patients showed no statistically significant difference in myocardial infarction rates at 30 days between ERAH and ORAH (0.80, 95% CI = 0.30 to 2.10, P = 0.64). A pooled analysis of nine studies including 2362 patients showed no statistically significant difference in all-cause mortality at 30 days between ERAH and ORAH (OR = 0.62, 95% CI = 0.15 to 2.67, P = 0.52). Similarly, there was no statistically significant in all-cause mortality up to 5-year follow-up (OR = 0.64, 95% CI = 0.30 to 1.37, 3 studies, 333 patients, P = 0.25). One study including 164 patients found no significant difference between ERAH and ORAH in the odds of death, myocardial infarction, or revascularization at up to 5-year follow-up (OR = 0.54, 95% CI = 0.20 to 1.46).
Few trials reported on angiographic outcomes. A pooled analysis of five studies including 652 grafts showed no difference in radial graft patency between ERAH and ORAH at up to 1-year follow-up (OR = 1.24, 95% CI = 0.68 to 2.25, P = 0.48). Similarly, a pooled analysis of three studies including 632 grafts showed no difference in radial graft patency between ERAH and ORAH at 3-to 5-year follow-up (OR = 1.81, 95% CI = 1.01 to 3.25, P = 0.05).
Statements
ERAH does not demonstrate a reduction in angiographic pa-
tency over ORAH at 1 year (level B-R) or at 3-to 5-year follow-up (level B-R) 2. ERAH is not associated with a reduction in perioperative myocardial infarction over ORAH (level B-R) 3. ERAH is not associated with a reduction in mortality at 30 days and at 3 to 5 years over ORAH (level B-R). 4. There was no difference in composite of death, myocardial infarction, or revascularization up to 4-year follow-up (level B-NR).
Recommendation
Based on major adverse cardiac events and angiographic patency, ERAH is noninferior to ORAH technique (class III, level B-R).
Pain, Mobility, and Sensory Dysfunction
Question: Does EVH improve patient satisfaction and reduce pain when compared with OVH in CABG?
EVH Versus OVH
The odds of moderate to severe pain during the postoperative period were significantly reduced by 81% with EVH compared with OVH (OR = 0.19, 95% CI = 0.11 to 0.34, 7 studies, 834 patients, P < 0.00001) and by 90% at 6-month follow-up (OR = 0.10, 95% CI = 0.03 to 0.37, 1 study, 108 patients, P = 0.0005). Similarly, a visual analog score for pain on postoperative days 1 to 3 was significantly reduced by nearly 1 point with EVH compared with OVH (MD = −0.95, 95% CI = −1.61 to −0.28, 9 studies, 1462 patients, P = 0.005) and was also significantly reduced at 3-to 6-week follow-up (MD = −0.60, 95% CI = −0.87 to −0.33, 5 studies, 509 patients).
The odds of mobility disturbance at discharge were reduced by 69% with EVH compared with OVH (OR = 0.31, 95% CI = 0.15 to 0.65, 3 studies, 572 patients, P = 0.002). The odds of postoperative sensory disturbance (ie, neuralgia) were reduced by 74% with EVH compared with OVH (OR = 0.26, 95% CI = 0.09 to 0.74, 2 studies, 357 patients, P = 0.01). Similarly, the odds of sensory disturbance at 3-to 6-week follow-up were reduced by 74% with EVH compared with OVH (OR = 0.26, 95% CI = 0.15 to 0.45, 8 studies, 1206 patients, P < 0.00001) and by 82% at 3-to 6-month follow-up (OR = 0.18, 95% CI = 0.08 to 0.42, 2 studies, 237 patients, P < 0.0001).
Question: Does ERAH improve patient satisfaction and reduce pain when compared with ORAH in CABG?
ERAH Versus ORAH
The odds of pain during the postoperative period were significantly reduced by 72% with ERAH compared with ORAH (OR = 0.28, 95% CI = 0.13 to 0.62, 2 studies, 196 patients, P = 0.002). Similarly, a pooled analysis of two studies reporting on a postoperative pain score showed a significant reduction of 2 points with ERAH compared with ORAH (MD = −2.01, 95% CI = −2.12 to −1.89, 283 patients, P < 0.00001). One study reported a reduction in upper limb pain and improvement in mobility at 9-month follow-up (OR = 0.06, 95% CI = 0.00 to 1.06, 164 patients, P = 0.05). 71 Patients in the ERAH group had significantly reduced odds of surgery affecting work or daily activities (OR = 0.04, 95% CI = 0.00 to 0.64, P = 0.02) and social activities (OR = 0.06, 95% CI = 0.01 to 0.48, P = 0.008) compared with the ORAH group at 9-month follow-up.
A pooled analysis of five studies (617 patients) showed that the odds of postoperative neuralgia were reduced by 42% with ERAH compared with ORAH (OR = 0.28, 95% CI = 0.13 to 0.62, P = 0.08). The odds of neuralgia were significantly reduced at 1 month (OR = 0.28, 95% CI = 0.15 to 0.53, 2 studies, 364 patients, P < 0.0001) and 6-to 9-month follow-up (OR = 0.15, 95% CI = 0.03 to 0.84, 2 studies, 364 patients, P = 0.03).
Patient Satisfaction EVH Versus OVH
Few studies reported on patient satisfaction. 20, 40, 41, 45, 101 Patients' satisfaction with pain relief during hospitalization was significantly improved with EVH compared with OVH (MD = 1.88 points, 95% CI = 1.49 to 2.28, 1 study, 144 patients) but was no longer significant at 6-week follow-up (MD = 0.24 points, 95% CI = −0.09 to 0.57, P < 0.00001). Patient satisfaction with ambulation at hospital discharge was significantly improved with EVH compared with OVH (MD = 2.40, 95% CI = 2.02 to 2.75, 1 study, 144 patients, P < 0.00001). Endoscopic vein harvest patients were less likely than OVH patients to be dissatisfied with surgery (OR = 0.17, 95% CI = 0.05 to 0.61, 1 study, 134 patients) and less likely to be dissatisfied with the cosmetic results of surgery (OR = 0.25, 95% CI = 0.10 to 0.64, 2 studies, 229 patients). Similarly, in a single trial reporting on a cosmetic score, 20 EVH patients were significantly more likely than OVH patients to be satisfied with the cosmetic results of surgery (MD = 0.70, 95% CI = 0.39 to 1.01, 129 patients, P < 0.0001).
ERAH Versus ORAH
Only two studies assessing ERAH reported on patients' satisfaction. 26, 29 Overall patient satisfaction was significantly higher in ERAH patients compared with ORAH (MD = 4.63 points, 95% CI = 3.91 to 5.35, 1 study, 119 patients, P < 0.00001). Overall patient satisfaction and cosmesis were significantly better in the endoscopic group at postoperative day 2 (P < 0.001), at discharge (P < 0.001), and at 6-week follow-up (P < 0.001). One study reporting on a cosmetic result score found that ERAH patients were significantly more likely than ORAH patients to be satisfied with the cosmetic results of surgery (MD = 1.10 points, 95% CI = 0.79 to 4.41, 228 patients, P < 0.00001).
Statements
1. EVH is associated with an increase in patient satisfaction, satisfaction with cosmesis and mobility (level A). 2. EVH is associated with a reduction in the incidence (level A) and severity (level B-NR) of postoperative pain, in the severity of pain at 3 to 6 weeks (level A), and in the incidence at 6-month follow-up (level B-R). 3. EVH is associated with a reduction in the incidence of sensory dysfunction postoperatively, at 3-to 6-week follow-up and at 6-month follow-up (level A)
Recommendation
Endoscopic vein harvest is recommended for vein harvesting to improve patient satisfaction and postoperative pain when compared with OVH (class I, level A).
Statements
ERAH is associated with an increase in patient satisfaction
compared with ORAH (level B-R) and an increase in patient satisfaction regarding cosmesis (level B-NR). 2. ERAH is associated with a reduction in postoperative pain compared with ORAH (level B-R). 3. ERAH is associated with a reduction in neurological dysfunction compared with ORAH at 1 month and at 6 to 9 months (level B-NR).
Recommendation
The endoscopic approach is recommended for radial artery harvesting to improve patient satisfaction and postoperative pain (class I, Level B-NR).
Resource Use
Question: Does EVH affect resource use when compared with OVH in CABG?
EVH Versus OVH
The mean time required to harvest the graft was significantly increased with EVH compared with OVH (MD = 7.74 minutes, 95% CI = 0.78 to 14.70, 22 studies, 6251 patients, P = 0.03). 
Statements
1. Time to harvest is increased but closure time is decreased in EVH; overall surgery duration is no different (level B-R). 2. EVH is associated with an overall reduction in postoperative LOS (level A). 3. There is no difference in the incidence of readmission for wound complications; however, EVH is associated with a reduced need for outpatient wound management resources including need for antibiotics, nursing or homecare, and emergency room or department (ER) or MD visits (level A).
Recommendation
Endoscopic vein harvest is recommended for vein harvesting to reduce postoperative LOS and outpatient wound management resources (class I, level A). Centers that are interested in adopting EVH should not be concerned with an increased length of time required for vein harvesting because there was no difference in overall harvest time because of a reduction in closure time (class III, level B-R).
ERAH Versus ORAH
The mean time required to harvest the graft was significantly increased with ERAH compared with ORAH (MD = 19.6 minutes, 95% CI = 12.71 to 26.49, 4 studies, 304 patients, P < 0.00001). There was no statistically significant difference in total operative time (MD = 4.92 minutes, 95% CI = −7.92 to 17.77, 2 studies, 357 patients, P = 0.45).
Although the total hospital and ICU LOS was reduced with ERAH compared with ORAH, these differences were not statistically significant. The MD in hospital LOS was −4.07 days (95% CI = −11.53 to 3.39, 2 studies, 264 patients, P = 0.28). The MD in ICU LOS was −1.10 days (95% CI = −3.36 to 1.16, 1 study, 100 patients, P = 0.34). One study including 100 patients found no difference in surgical interventions for wound complications (OR = 0.33, 95% CI = 0.01 to 8.21, P = 0.50).
DISCUSSION
This consensus conference and the statements generated update the previous the ISMICS consensus conference in two important ways: (1) we have updated the analysis to include all relevant studies that have been conducted since 2005 and (2) we have included radial artery harvesting in the analysis.
Because the field of endoscopic harvesting of saphenous vein has progressed in terms of technology and adoption, additional studies have been added to the body of literature. With more widespread adoption, evaluation of the outcomes with this technique has generated greater interest and is more feasible in terms of having additional time intervals postprocedure for more robust follow-up studies. The additional experience and wider adoption of endoscopically harvested saphenous vein EVH have also facilitated the application of this technique to the radial artery (ERAH), which has become more widely used. Thus, adding analysis of this conduit to the consensus conference and statements is timely.
Consistent with the previous consensus conference findings, the morbidities associated with harvesting conduit for surgical revascularization are all significantly less with the endoscopic technique. However, three areas had associated concern. Resource use must be addressed because harvesting conduit endoscopically requires additional equipment, the cost of which could conceivably outweigh the potential benefits. Furthermore, the quality of the conduit harvested with the endoscopic technique and whether there is any negative effect on conduit patency, and lastly, any potential adverse cardiac events would be of prime concern.
Resource Use EVH Versus Open
Studies reported a higher per-patient cost in OVH versus EVH because the rate of wound complication of OVH was significantly higher. However, it has been stated otherwise for different points of view: from patients, surgeons, hospitals, health care systems, and industries. Few researchers took all the aspects into account, such as in-hospital cost, medication, readmission, and initial investments. In addition, most of the studies, often termed "partial economic evaluation studies," are less useful for decision making, because these studies only compared the costs of technologies and not effectiveness.
Two studies comparing the cost-effectiveness analysis (CEA) and the cost-utility analysis were found in our systemic review but indicate opposite results. Rao et al 109 reported that EVH was cost-effective within the first 6 weeks postoperatively, with an incremental cost-effectiveness ratio of US $19,858.87/ quality-adjusted life-year (QALY) and the sensitivity analysis showed, with a probability of 95.6%, that EVH would be costeffective (with a ratio below US $50,000/QALY) (class IIb). 109 Oddershede et al 110 showed a US $79,391/QALY and a 96.7% probability of being cost-effective in their study (class IIa). Oddershede et al 110 argued that the study by Rao et al 109 did not include costs of initial investments, readmissions, and additional treatment due to donor site infections and the patients in the study by Rao et al 109 did not receive sufficient treatment for their pain, which may have led to an overestimation of the reduction in postoperative pain by EVH. However, in our systematic review and meta-analysis, the odds of moderate to severe pain during postoperative period were significantly reduced by 81% with EVH compared with OVH, and initial investments would gradually decrease with the increasing number of patient receiving EVH. The study by Oddershede et al 110 had only 35-day follow-up as compared with the study of 42 days by Rao et al 109 ; thus, the latter might yield a better assessment on the effect of EVH. Clearly, further studies looking at the long-term CEA of EVH versus OVH are needed.
ERAH Versus ORAH
Cost analyses and cost-effectiveness analyses were rarely conducted in studies of ERAH and ORAH. There are limited data to base recommendations on the resource use of the two techniques. Although there are relevant results for ERAH versus ORAH in wound complication, pain, mobility, and sensory dysfunction, the CEA of ERAH versus ORAH might be similar. As noted with EVH, long-term CEA is needed.
Graft Patency EVH Versus Open
Graft patency is a central issue in the conversation regarding the utility of EVH and has been widely studied for the past several years since the last ISMICS consensus statement. Many different factors account for decreased vein graft patency over time. We therefore analyzed the clinical evidence available based on the time of angiographic follow-up. We considered the following time frames: early failure (up to 6 months, more likely to be related to surgical technique), midterm (1 year), and long term (>1 year).
As outlined in the results section, only a few of the clinical studies available allowed for a systemic comparison of graft patency between open and endoscopic harvesting techniques. Early graft failure (within 6 months) was not influenced by the harvesting technique. Graft patency at 1 year seemed to be worse in patients undergoing EVH as mostly inferred from a secondary post hoc analysis of the ROOBY trial. 3 It should be stressed that although the ROOBY trial was a prospective randomized trial (for coronary bypass technique), assignment to open or endoscopic harvesting was not randomized and this study was not powered to compare patency between open and EVH techniques. Another difficulty in making inferences regarding this topic from the ROOBY trial is the lack of information regarding the type of device (sealed or nonsealed) used for EVH. Since this study was conducted in the United States, it could be argued that the sealed device was more likely to have been used in these patients, because it was the more widely adapted technique in US centers. This is at a time before it was postulated that a sealed device may have a higher likelihood of developing strands of clot at the vein branches during endoscopic harvesting (thereby jeopardizing graft patency); and thus, the recommendation that heparinization should be a routine before taking the branches when using such a device to prevent graft occlusion. 111 Although no firm data are available, it is not mentioned in the study that patients received this treatment. Finally, the issue of variability in operator experience is important as mentioned by the authors of the study. 3 Conversely, our analysis revealed that long-term graft patency (>1 year) was not influenced by the technique of vein harvesting. These results were observed despite the inclusion of a secondary analysis of the PREVENT IV trial. 68 In this study, 85% of patients underwent EVH with a sealed system and did not receive preheparinization.
Besides the potential role of the endoscopic harvesting technique per se or the use of a specific system (ie, sealed or nonsealed), many additional factors not accounted for in these studies may also influence graft patency. These factors include graft preservation solutions, site of harvesting the vein (calf vs thigh, which would influence size discrepancy between vein conduit and coronary target), vein distension practices (which may lead to endothelial damage if too aggressive), and discharge on evidence-based secondary prevention medications. In addition, the role of training and operator experience has been briefly mentioned; however, this is an area that should be further explored, because the skill set for endoscopically harvesting conduit requires advanced training.
ERAH Versus ORAH
A similar analysis was performed with respect to graft patency after radial artery procurement with an open or endoscopic approach.
There was no difference in early graft patency (up to 1 year) between the two techniques. Of note, the studies evaluated in our analysis included the use of both sealed and nonsealed systems. Furthermore, the studies in which ERAH was performed with a sealed system were conducted after the introduction of preheparinization in clinical practice. This may have accounted for the excellent outcomes with this approach.
At long-term follow-up (>1 year), the use of an endoscopic approach to radial artery harvesting seems to yield superior graft patency when compared with the open technique.
It is possible that the seemingly better outcomes of endoscopic harvesting of the radial artery as opposed to the saphenous vein graft are that operators usually get through their learning curve during vein harvesting and are generally more experienced in the technique by the time they start using it on the radial artery.
Mortality
With any change in practice, including using new techniques and/or technology, the effects (positive, negative, or neutral) in mortality rates are of primary concern to patients and surgeons. In the initial ISMICS consensus statements published in 2005, there was not found to be an important difference in cardiac events or angiographic patency between endoscopic or open harvested saphenous vein.
1,2 After these consensus statements were published, a post hoc analysis of a randomized trial (PREVENT IV) looking at the role of ex vivo treatment of vein grafts with the E2F transcription factor decoy, edifoligide, in patients undergoing CABG on adverse clinical outcomes and vein graft patency was published. 68 This had generated a fair amount of controversy because the study was deemed to be "prospectively randomized." However, the miss-interpretive risks of focusing on a single retrospective post hoc analysis to determine prognostic differences are high. 112 Differing institutional outcomes, techniques, equipment or devices, and operator experience are all confounding variables that can lead to erroneous conclusions. 113 Our conclusions, based on rigorously analyzed, high-quality evidence, demonstrate no increase in major adverse cardiac events or decrease in graft patency for endoscopically harvested saphenous vein or radial artery. Thus, the present consensus conference, systemic review with meta-analysis, and generated statements will provide useful guidance to patients, surgeons, and all other stakeholders on best practices for harvesting saphenous vein or radial artery for CABG procedures.
Limitations
This consensus statement is the work product of an international panel of experts' analysis of a comprehensive metaanalysis and systemic review of the current medical literature. As such, only data on EVH and ERAH included in published studies provided the evidence and informed conclusions. Lack of additional studies specific to individual topics such as resource use and cost analysis, long-term angiographic follow-up, as well as issues related to standardized definitions must be recognized and used to inform and plan future research in this field. Additional topics such as the training and skill of the individual harvesting the conduit and the effect of secondary prevention with evidence-based medical therapy would also add meaningfully to the body of literature on the techniques and technology for harvesting conduit and the long-term outcomes.
